NCT01714739 arm group 848de2a5a4e74547b55031b7d43a46f7 [clinicaltrials_resource:NCT01714739/arm-group/848de2a5a4e74547b55031b7d43a46f7]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01714739 arm group 848de2a5a4e74547b55031b7d43a46f7 [clinicaltrials_resource:NCT01714739/arm-group/848de2a5a4e74547b55031b7d43a46f7]
Bio2RDF identifier
NCT01714739/arm-group/848de2a5a4e74547b55031b7d43a46f7
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 8de2a5a4e74547b55031b7d43a46f7
description [clinicaltrials_vocabulary:description]
Lirilumab 1 mg/kg solution int ...... 96 weeks depending on response
identifier
clinicaltrials_resource:NCT01714739/arm-group/848de2a5a4e74547b55031b7d43a46f7
title
NCT01714739 arm group 848de2a5a4e74547b55031b7d43a46f7
@en
type
label
NCT01714739 arm group 848de2a5 ...... de2a5a4e74547b55031b7d43a46f7]
@en